Literature DB >> 19360152

The molecular biology of pancreatic cancer.

Michael A Abramson1, Amarsanaa Jazag, Jill A van der Zee, Edward E Whang.   

Abstract

Pancreatic cancer is the fourth leading cause of cancer-related death in the United States. It is a highly aggressive malignancy for which currently available treatments are of only limited efficacy. For this reason, much research is directed at elucidating fundamental molecular mechanisms underlying the biology of pancreatic cancer. These efforts are generating a rapidly growing body of information. The yet unmet challenge is to translate this information into clinically applicable strategies for early detection, prediction of prognosis, and effective therapies for patients diagnosed with pancreatic cancer.

Entities:  

Year:  2007        PMID： 19360152      PMCID： PMC2666839     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


  77 in total

Review 1.  Multimodality approaches for pancreatic cancer.

Authors:  Gary Y Yang; Timothy D Wagner; Martin Fuss; Charles R Thomas
Journal:  CA Cancer J Clin       Date:  2005 Nov-Dec       Impact factor: 508.702

Review 2.  Pancreatic adenocarcinoma -- genetic portrait from chromosomes to microarrays.

Authors:  Ritva Karhu; Eija Mahlamäki; Anne Kallioniemi
Journal:  Genes Chromosomes Cancer       Date:  2006-08       Impact factor: 5.006

Review 3.  Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies.

Authors:  Murielle Mimeault; Randall E Brand; Aaron A Sasson; Surinder K Batra
Journal:  Pancreas       Date:  2005-11       Impact factor: 3.327

Review 4.  Molecular markers of early pancreatic cancer.

Authors:  Michael Goggins
Journal:  J Clin Oncol       Date:  2005-07-10       Impact factor: 44.544

Review 5.  Familial pancreatic cancer.

Authors:  A P Klein; R H Hruban; K A Brune; G M Petersen; M Goggins
Journal:  Cancer J       Date:  2001 Jul-Aug       Impact factor: 3.360

6.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

Review 7.  Molecular therapy in pancreatic adenocarcinoma.

Authors:  Mary J MacKenzie
Journal:  Lancet Oncol       Date:  2004-09       Impact factor: 41.316

8.  High-resolution characterization of the pancreatic adenocarcinoma genome.

Authors:  Andrew J Aguirre; Cameron Brennan; Gerald Bailey; Raktim Sinha; Bin Feng; Christopher Leo; Yunyu Zhang; Jean Zhang; Joseph D Gans; Nabeel Bardeesy; Craig Cauwels; Carlos Cordon-Cardo; Mark S Redston; Ronald A DePinho; Lynda Chin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-15       Impact factor: 11.205

9.  Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines.

Authors:  Markus Heidenblad; Eric F P M Schoenmakers; Tord Jonson; Ludmila Gorunova; Joris A Veltman; Ad Geurts van Kessel; Mattias Höglund
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

10.  CEACAM6 is a determinant of pancreatic adenocarcinoma cellular invasiveness.

Authors:  M S Duxbury; H Ito; E Benoit; S W Ashley; E E Whang
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640
View more
  10 in total

Review 1.  Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma.

Authors:  Wilson Petrushnko; Justin S Gundara; Philip R De Reuver; Greg O'Grady; Jaswinder S Samra; Anubhav Mittal
Journal:  HPB (Oxford)       Date:  2016-07-14       Impact factor: 3.647

Review 2.  Peptide-Based Therapeutics for Oncology.

Authors:  Elizaveta Fisher; Kirill Pavlenko; Alexander Vlasov; Galina Ramenskaya
Journal:  Pharmaceut Med       Date:  2019-02

Review 3.  Developing effective combination therapy for pancreatic cancer: An overview.

Authors:  Aubrey L Miller; Patrick L Garcia; Karina J Yoon
Journal:  Pharmacol Res       Date:  2020-03-02       Impact factor: 7.658

4.  Human pancreatic cancer progression: an anarchy among CCN-siblings.

Authors:  Sushanta K Banerjee; Gargi Maity; Inamul Haque; Arnab Ghosh; Sandipto Sarkar; Vijayalaxmi Gupta; Donald R Campbell; Daniel Von Hoff; Snigdha Banerjee
Journal:  J Cell Commun Signal       Date:  2016-08-19       Impact factor: 5.782

5.  Autophagy in pancreatic cancer pathogenesis and treatment.

Authors:  Rui Kang; Daolin Tang
Journal:  Am J Cancer Res       Date:  2012-06-28       Impact factor: 6.166

6.  The MAZ transcription factor is a downstream target of the oncoprotein Cyr61/CCN1 and promotes pancreatic cancer cell invasion via CRAF-ERK signaling.

Authors:  Gargi Maity; Inamul Haque; Arnab Ghosh; Gopal Dhar; Vijayalaxmi Gupta; Sandipto Sarkar; Imaan Azeem; Douglas McGregor; Abhishek Choudhary; Donald R Campbell; Suman Kambhampati; Sushanta K Banerjee; Snigdha Banerjee
Journal:  J Biol Chem       Date:  2018-02-06       Impact factor: 5.157

7.  Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study.

Authors:  Volker Kunzmann; Ramesh K Ramanathan; David Goldstein; Helen Liu; Stefano Ferrara; Brian Lu; Markus F Renschler; Daniel D Von Hoff
Journal:  Pancreas       Date:  2017-02       Impact factor: 3.327

Review 8.  Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models.

Authors:  Patrick L Garcia; Aubrey L Miller; Karina J Yoon
Journal:  Cancers (Basel)       Date:  2020-05-22       Impact factor: 6.639

9.  Peroxisome proliferator-activated receptor gamma and regulations by the ubiquitin-proteasome system in pancreatic cancer.

Authors:  Athina Stravodimou; Gianluigi Mazzoccoli; Ioannis A Voutsadakis
Journal:  PPAR Res       Date:  2012-09-19       Impact factor: 4.964

10.  Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes.

Authors:  Eileen M O'Reilly; Paul Cockrum; Andy Surinach; Zheng Wu; Allison Dillon; Kenneth H Yu
Journal:  Cancer Med       Date:  2020-09-30       Impact factor: 4.452
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.